Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis

Yu Xiao, Jing Fu, Juan Li, Gang Hu · 2026

Read Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis by Yu Xiao, Jing Fu, Juan Li, Gang Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358540.txt.

Description

Xiao and three co-authors published a 2026 PLOS ONE study comparing drugs for advanced breast cancer. All the cancers were HER2-positive and had spread. The team weighed one drug, T-DXd, against other HER2-targeted options used after first treatment failed. They used a Bayesian network method that pools many trials at once. Rankings like this help doctors choose when no single trial compares every option.

Catalog record

CREATORYu Xiao, Jing Fu, Juan Li, Gang Hu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51274
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0358540

Browse the full library · About the Tower of Babel